FUM.L (Mkap 15 M€) Best in Class Erektionsmittel in P3 (Daten im 2H 2019) (Seite 17)
eröffnet am 04.01.19 11:01:05 von
neuester Beitrag 08.01.24 15:14:53 von
neuester Beitrag 08.01.24 15:14:53 von
Beiträge: 932
ID: 1.295.522
ID: 1.295.522
Aufrufe heute: 0
Gesamt: 126.446
Gesamt: 126.446
Aktive User: 0
ISIN: GB0033278473 · WKN: 911670 · Symbol: FUM
0,3650
GBP
+7,35 %
+0,0250 GBP
Letzter Kurs 15:26:51 London
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 13,110 | +38,44 | |
| 1,2100 | +21,00 | |
| 27,50 | +19,57 | |
| 4,4900 | +19,10 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,4500 | -20,55 | |
| 36,70 | -22,87 | |
| 2,3450 | -25,32 | |
| 15,600 | -31,64 | |
| 2,5600 | -70,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Seid ihr einstiegen vor dem Call heute?
Ein paar Tage verschoben, aus dem UK-Forum:
The new date is 1st April, this is what they said a couple of days ago; James Barder, Chief Executive Officer, Angela Hildreth, Finance Director/Chief Operating Officer, and Ken James, Executive Director and Head of R&D, will host a webcast for analysts on the day of the results, which will be made available within the investor centre section of the Company's website. In light of growing concerns regarding COVID-19, the Company has decided to cancel its scheduled Investor Seminar, to be held on 26 March 2020. The Results webcast will now incorporate the Investor Seminar presentation which includes an extensive internal evaluation of the clinical data from the Phase 3 study ("FM57"), ongoing research and analysis of MED3000, as well as an update on regulatory discussions and insight into the erectile dysfunction market presented by Professor David Ralph, world leading expert in erectile dysfunction and male infertility and member of the Futura European KOL Advisory Panel.
The new date is 1st April, this is what they said a couple of days ago; James Barder, Chief Executive Officer, Angela Hildreth, Finance Director/Chief Operating Officer, and Ken James, Executive Director and Head of R&D, will host a webcast for analysts on the day of the results, which will be made available within the investor centre section of the Company's website. In light of growing concerns regarding COVID-19, the Company has decided to cancel its scheduled Investor Seminar, to be held on 26 March 2020. The Results webcast will now incorporate the Investor Seminar presentation which includes an extensive internal evaluation of the clinical data from the Phase 3 study ("FM57"), ongoing research and analysis of MED3000, as well as an update on regulatory discussions and insight into the erectile dysfunction market presented by Professor David Ralph, world leading expert in erectile dysfunction and male infertility and member of the Futura European KOL Advisory Panel.
Nächste Woche, 26. März gibt’s die neue Präsentation.
Lt. UK-Forum notfalls per Webcast...
Lt. UK-Forum notfalls per Webcast...
Es tut sich was...👌
In addition, following positive interactions with an EU Notified Body announced in February 2020, we look forward to providing the market with further updates regarding the formal proceedings of MED3000 to be approved as a medical for treatment of ED."
In addition, following positive interactions with an EU Notified Body announced in February 2020, we look forward to providing the market with further updates regarding the formal proceedings of MED3000 to be approved as a medical for treatment of ED."
Futura Medical to Present "FM57" Clinical Data and Provide Update on MED3000 at Investor Seminar in March 2020
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its on its proprietary, transdermal technology DermaSys® and currently focused on sexual health and pain, announces plans to host an Investor Seminar in London for analysts and institutional investors on Thursday, 26 March 2020.
The seminar follows an extensive internal evaluation of the clinical data from the Phase 3 study ("FM57") announced on 10 December 2019. Ken James, Executive Director and Head of R&D will present the Company's ongoing research and analysis of the FM57 and MED3000.
James Barder, Chief Executive Officer of Futura Medical, said: "FM57 results demonstrate that MED3000 is a highly effective, safe and differentiated therapy for ED. After an extensive internal evaluation of the FM57 clinical data, we are pleased to be able to share our ongoing clinical and literature-based research and analysis, examining MED3000 efficacy and modes of action in ED. In addition, following positive interactions with an EU Notified Body announced in February 2020, we look forward to providing the market with further updates regarding the formal proceedings of MED3000 to be approved as a medical for treatment of ED."
The seminar will also feature a presentation from Professor David Ralph, world leading expert in erectile dysfunction and male infertility and member of the Futura European KOL Advisory Panel, providing an insight into the ED market.
Professor David Ralph is a leading Consultant in the field of Andrology. He practices both privately and on the NHS, and holds a senior consultant post at the University College London Hospital. He is a Professor at the Cranfield University and is a senior lecturer at the Institute of Urology, London. Professor David's main areas of expertise are penile implants, total genital reconstruction, Peyronie's disease and male infertility. He is internationally recognised for his work.
For further information on the Investor Seminar, or to register your interest, please contact Optimum Strategic Communications at futuramedical@optimumcomms.com. Further information will be made available in March 2020.
The event will be webcast and will be made available on the investor section of website shortly after the event.
-ENDS-
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Futura Medical plc (AIM: FUM) ("Futura" or the "Company"), a pharmaceutical company developing a portfolio of innovative products based on its on its proprietary, transdermal technology DermaSys® and currently focused on sexual health and pain, announces plans to host an Investor Seminar in London for analysts and institutional investors on Thursday, 26 March 2020.
The seminar follows an extensive internal evaluation of the clinical data from the Phase 3 study ("FM57") announced on 10 December 2019. Ken James, Executive Director and Head of R&D will present the Company's ongoing research and analysis of the FM57 and MED3000.
James Barder, Chief Executive Officer of Futura Medical, said: "FM57 results demonstrate that MED3000 is a highly effective, safe and differentiated therapy for ED. After an extensive internal evaluation of the FM57 clinical data, we are pleased to be able to share our ongoing clinical and literature-based research and analysis, examining MED3000 efficacy and modes of action in ED. In addition, following positive interactions with an EU Notified Body announced in February 2020, we look forward to providing the market with further updates regarding the formal proceedings of MED3000 to be approved as a medical for treatment of ED."
The seminar will also feature a presentation from Professor David Ralph, world leading expert in erectile dysfunction and male infertility and member of the Futura European KOL Advisory Panel, providing an insight into the ED market.
Professor David Ralph is a leading Consultant in the field of Andrology. He practices both privately and on the NHS, and holds a senior consultant post at the University College London Hospital. He is a Professor at the Cranfield University and is a senior lecturer at the Institute of Urology, London. Professor David's main areas of expertise are penile implants, total genital reconstruction, Peyronie's disease and male infertility. He is internationally recognised for his work.
For further information on the Investor Seminar, or to register your interest, please contact Optimum Strategic Communications at futuramedical@optimumcomms.com. Further information will be made available in March 2020.
The event will be webcast and will be made available on the investor section of website shortly after the event.
-ENDS-
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
www.futuramedical.com
Trading Spotlight
Starke Vorstellung auch heute wieder, 15£ in Reichweite 💪
Mit der heutigen Meinung eines Users aus dem UK-Forum gehe ich überein:
It will be interesting to see how the share price moves over the next 18 months. Value Inflection points of two submissions; EU mid year and FDA at some point. Hopefully followed by approvals within 12 months of that. I suspect territory deals will be struck rather than a global partner and that these could come at any time. Although there are other indications all the value seems to attached to ED. Perhaps a steady rise in the share price as peeps realise the value here or leaps as inflection points are met? Time will tell I guess, I am new here but the risk/reward looks attractive.
Mit der heutigen Meinung eines Users aus dem UK-Forum gehe ich überein:
It will be interesting to see how the share price moves over the next 18 months. Value Inflection points of two submissions; EU mid year and FDA at some point. Hopefully followed by approvals within 12 months of that. I suspect territory deals will be struck rather than a global partner and that these could come at any time. Although there are other indications all the value seems to attached to ED. Perhaps a steady rise in the share price as peeps realise the value here or leaps as inflection points are met? Time will tell I guess, I am new here but the risk/reward looks attractive.
Sehr schön, erst die Geldspritze von Lombard & jetzt auch noch auf 20% erhöht, Lombard muß sich seiner Sache ziemlich sicher sein...
Antwort auf Beitrag Nr.: 62.701.999 von Stoxtrayder am 17.02.20 13:54:52Lombard hat seinen Anteil auf über 20 Prozent erhöht:
https://futuramedical.com/investor-centre/rns/
Und auch die Sun schreibt über Med3000:
https://www.thesun.co.uk/news/10974387/new-erectile-dysfunct…
https://futuramedical.com/investor-centre/rns/
Und auch die Sun schreibt über Med3000:
https://www.thesun.co.uk/news/10974387/new-erectile-dysfunct…
Ca. 4% Plus gerade...Umsätze jedoch ausbaufähig 😉
Sehr schön, Danke für den Link! 👍
Könnte morgen für ‚nen kleinen Kursschub sorgen in UK...
Könnte morgen für ‚nen kleinen Kursschub sorgen in UK...
Durchsuchen
